Zydus Lifesciences Limited has informed the Exchange regarding a press release dated May 28, 2025, titled "Zydus receives USFDA Fast Track Designation for Usnoflast, a novel oral NLRP3 inhibitor, for the treatment of Amyotrophic Lateral Sclerosis (ALS)".
Press Release May 28 2025
Filed with NSE · · 4 pages · English
Summary by 6ix AI
This designation facilitates expedited development and review of the drug, highlighting the urgent need for effective treatments for ALS. The company previously received Orphan Drug Designation for Usnoflast, which provides additional development incentives.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release May 23 2025
- Press Release May 20 2025
- Press Release May 14 2025
- Press Release May 08 2025
- Zydus Receives Final Approval From USFDA for Glatiramer Acetate Injection, the Generic Version of Copaxone® 20 mg/ml, 40 mg/ml, Single-Dose Prefilled Syringes
Later from Zydus Lifesciences
- Zydus Lifesciences Limited Press Release Jun 02 2025
- Press Release Jun 10 2025
- Press Release Jun 11 2025
- Press Release Jun 18 2025
- Press Release Jul 15 2025
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences